1)Wang CH, et al : Consensus statement on standard of care for congenital myopathies. J Child Neurol 27 : 363-382, 2012
2)Shieh PB, et al : Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy(ASPIRO) : a multinational, open-label, dose-escalation trial. Lancet Neurol 22 : 1125-1139, 2023
3)Colombo I, et al : Congenital myopathies : natural history of a large pediatric cohort. Neurology 84 : 28-35, 2015
4)Yamamoto T, et al : Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy(SMA)patients. Brain Dev 36 : 914-920, 2014
5)Strauss KA, et al : Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1 : the Phase III SPR1NT trial. Nat Med 28 : 1381-1389, 2022